# Epitalon Research: Telomerase, Pineal Melatonin, and the Khavinson Peptide Program

> Epitalon research summarised: hTERT induction in human cell lines, melatonin restoration in elderly cohorts, rodent cancer-model results, and the historical context of the Khavinson St. Petersburg peptide program.

An organised reading of the peer-reviewed evidence — cellular mechanism first, animal models second, the small human cohort record third, and the historical Khavinson program as context.

## Epitalon Mechanism of Action

The Epitalon mechanism of action centres on three proposed pathways, layered from most directly evidenced to most inferred. First and most reproducibly: induction of hTERT expression and telomerase activity in human somatic cells, with telomere elongation as the downstream measurement [1][2]. Second: direct binding to DNA promoter regions and to histone proteins — the 2020 Khavinson *Molecules* paper used molecular modelling to propose preferential AEDG binding to histones H1/3 and H1/6 at their DNA-interactive sites, with downstream upregulation of neurogenic differentiation markers (Nestin, GAP43, β-tubulin III, Doublecortin) by 1.6 to 1.8-fold in human gingival mesenchymal stem cells [3]. Third: restoration of nocturnal melatonin secretion in subjects with pineal hypofunction, demonstrated for the parent extract Epithalamin in elderly humans [11] and the AEDG-related preparation in aged rhesus monkeys [12].

## Epitalon and Telomerase Activation

The single most-cited mechanism for Epitalon is telomerase activation. In 2003, Khavinson, Bondarev and Butyugov reported in *Bulletin of Experimental Biology and Medicine* that adding the peptide to telomerase-negative human fetal fibroblast cultures induced expression of the telomerase catalytic subunit, restored enzymatic telomerase activity, and elongated telomeres in previously telomerase-silent cells [1]. The finding sat in the literature largely unreplicated outside the Khavinson program for two decades. In 2025, Al-dulaimi and colleagues published an independent replication in *Biogerontology*: in normal human fibroblasts (IBR.3) and mammary epithelial cells (HMEC), AEDG upregulated hTERT mRNA and telomerase activity with telomere length increase; in breast cancer cell lines (21NT and BT474) the same exposure produced little change in telomerase enzymatic activity but a roughly ten-fold rise in ALT (Alternative Lengthening of Telomeres) activity in the 21NT line [2]. The differential — telomerase upregulation in normal cells, ALT activation in some cancer lines — is one of the open questions the modern literature has raised.

## Proposed telomerase-activation mechanism

The proposed model: AEDG binds to specific gene promoter regions and increases hTERT transcription, leading to elongation of telomeric repeats in cultured human cells [1][3]. The 2020 epigenetic-mechanism paper from the Khavinson group provided the histone-binding refinement — molecular docking predicted AEDG binds histones H1/3 and H1/6 at their DNA-contact surfaces, suggesting a chromatin-level rather than purely transcription-factor-level intervention [3]. The mechanism remains under active investigation; the 2025 Araj review explicitly identifies the precise binding-and-transcription cascade as an outstanding question even after twenty-five years of work [15].

## Epithalamin vs Epitalon: From Pineal Extract to Synthetic Tetrapeptide

Epithalamin and Epitalon are not interchangeable. Epithalamin is a crude polypeptide extract of bovine pineal gland — a complex mixture of peptides and amino acids — that the Khavinson program studied from the 1970s onward, with reported effects on melatonin rhythm, immune function, and lifespan in animal models [11][14]. Epitalon is the synthetic defined-sequence tetrapeptide AEDG, designed from the amino-acid profile of Epithalamin to reproduce a portion of its activity in a chemically clean form [14]. Most of the clinical-cohort data attributed in consumer media to 'Epitalon' is in fact data on Epithalamin — the 2004 Korkushko elderly-melatonin paper, for example, dosed intramuscular Epithalamin and reported melatonin normalisation in subjects with pineal hypofunction [11]. The distinction is not a quibble: a crude extract has a different regulatory, pharmacokinetic, and reproducibility profile than a defined synthetic peptide.

## The Khavinson Peptide Program and the Origin of Epitalon

Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology developed Epitalon in the late 1980s and 1990s as part of a broader research program on short peptide bioregulators [1][14]. The program's working hypothesis: short peptides derived from tissue extracts act as tissue-specific gene-expression regulators, restoring function in age-impaired tissues. Epitalon was the pineal-derived member of a family that also includes Thymalin (thymus-derived), Vilon (immune), and Cortexin (cortex-derived). The 2002 *Neuro Endocrinology Letters* supplement-length monograph 'Peptides and Ageing' by Khavinson is the program's narrative summary: twenty-five years of work across rodent lifespan, primate melatonin, and small elderly cohorts, reported predominantly in Russian-language and Bulletin-of-Experimental-Biology-and-Medicine venues [14]. Independent Western replication of the lifespan and cohort-mortality findings remains limited.

## Pineal Gland Origin and Melatonin Effects

Epitalon's pineal origin runs through both its design history and its proposed mechanism. The parent extract Epithalamin was prepared from bovine pineal gland, and the AEDG sequence was designed from that extract's amino-acid composition [14]. The pineal-axis pharmacology is the most heavily studied human-cohort endpoint: Korkushko and colleagues in 2004 reported that intramuscular Epithalamin courses normalised night-time melatonin secretion in elderly subjects, with subjects having reduced baseline pineal activity showing the largest increases and subjects with preserved baseline showing a downward trend [11]. The 2007 multi-cohort extension reported similar melatonin-normalisation in aged rhesus monkeys treated with pineal-peptide preparations [12]. Whether the synthetic AEDG tetrapeptide alone (as opposed to the parent extract) produces the same melatonin signal in a modern controlled human trial remains untested in the published Western record.

## Reported effects in the published literature

Studied effects in the peer-reviewed record cluster into four families. Cellular: telomerase induction, telomere elongation, ALT-pathway differential in cancer lines [1][2]. Genomic-regulatory: histone binding and upregulation of neurogenic differentiation markers in mesenchymal stem cells [3]. Rodent geroprotection: reduced spontaneous tumor frequency in HER-2/neu mice [4][5], reduced DMH-induced colon carcinogenesis in LIO rats [8], reduced malignant-tumor incidence and metastasis prevention in C3H/He mice [7], slowed reproductive ageing in SHR mice with cytogenetic-damage reduction [6], modified survival under altered illumination regimes [10], extended maximum lifespan in the longest-living 10% of SAMP-1 mice [9]. Human cohort: melatonin rhythm normalisation in elderly subjects with pineal hypofunction [11][12], improved bioelectric retinal activity in 90% of a retinitis pigmentosa series [13].

## Animal-model evidence

Rodent geroprotection is the densest portion of the Epitalon record. In female HER-2/neu transgenic mice, monthly 5-day courses of 1 microgram/mouse subcutaneous reduced cumulative tumor number and maximum mammary-tumor size versus saline (p < 0.05) and reduced HER-2/neu oncogene mRNA by 3.7-fold [4][5]. In Swiss-derived SHR mice on the same monthly protocol from age 3 months, the peptide slowed age-related estrous-function loss and reduced chromosome-aberration frequency in bone-marrow cells by 17.1%; mean lifespan was unchanged, with the cumulative ~30-40 microgram/kg monthly exposure [6]. In C3H/He mice, 0.1 microgram/mouse five days per week for 6.5 months reduced malignant-tumor incidence and prevented metastases without observable toxicity [7]. In male LIO rats, weekly subcutaneous Epitalon alongside DMH challenge (21 mg/kg) suppressed colon-adenocarcinoma multiplicity and size [8]. In SAMP-1 senescence-accelerated mice, both melatonin and Epitalon preserved estrous cycling; Epitalon extended maximum lifespan in the longest-living 10% of animals without shifting overall tumor incidence [9]. In LIO rats under varying illumination regimes, monthly Ala-Glu-Asp-Gly (0.1 microgram/rat) partly compensated the lifespan-shortening effect of constant light [10].

## Human studies

Human studies of Epitalon and its parent extract Epithalamin exist but are limited in number, geographic distribution, and methodological scale. The Korkushko 2004 paper in *Bulletin of Experimental Biology and Medicine* reported that intramuscular Epithalamin courses normalised nocturnal melatonin secretion in elderly subjects with reduced pineal function [11]. The 2007 *Advances in Gerontology* multi-cohort paper extended the melatonin-normalisation finding across aged rhesus monkeys and elderly humans [12]. The 2002 retinitis pigmentosa series in *Neuro Endocrinology Letters* reported that parabulbar Epitalon (5 micrograms per eye for 10 consecutive days) improved bioelectric retinal activity and produced positive clinical response in 90% of treated patients [13]. As of 2026, ClinicalTrials.gov lists no large, modern, registered Western randomised controlled trials of the synthetic AEDG tetrapeptide [15] — and the 2025 Araj review in *International Journal of Molecular Sciences* identifies the absence of modern human trials as a primary outstanding gap [15].

## What does Epitalon do at the cellular level?

At the cellular level, Epitalon induces telomerase activity and telomere elongation in human somatic cell lines — replicated across the seminal 2003 Khavinson fetal-fibroblast work and the 2025 Al-dulaimi normal-fibroblast and epithelial-cell replication [1][2]. In stem cells, the peptide upregulates neurogenic differentiation markers via a proposed epigenetic mechanism of histone H1/3 and H1/6 binding [3]. In some cancer cell lines, the peptide selectively activates the ALT (Alternative Lengthening of Telomeres) pathway rather than telomerase — a differential first reported in the 2025 Biogerontology paper [2].

## Recent findings

Two 2025 papers reset the modern reading of the literature. The Al-dulaimi *Biogerontology* paper provided the first major Western-indexed independent replication of telomere elongation in human cell lines via hTERT upregulation, with the additional ALT-pathway finding in breast cancer lines [2]. The Araj *International Journal of Molecular Sciences* review (Volume 26, Article 2691) consolidated twenty-five years of Epitalon evidence — geroprotective, antioxidant, neuroprotective, antimutagenic — and identified the unresolved gaps: validated pharmacokinetic data, modern toxicology packages, large registered human trials [15]. The 2020 *Molecules* paper proposing the histone-binding epigenetic mechanism remains the structural-mechanism reference [3].

---

A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named.